Seeking Alpha
All posts from Seeking Alpha
Seeking Alpha in Seeking Alpha - Read, Decide, Invest.,

What The Chances Are Of BEACON's Success And What That Will Mean To Nektar

2014 was a banner year for Nektar Therapeutics (NKTR) of San Francisco. An adcom victory allowed retention of a $70M regulatory milestone payment from partner AstraZeneca (AZN). That led to the FDA approval of naloxegol, now commercially named MOVANTIK (MOVENTIG in Europe), and $140M of regulatory milestone payments tied to commercial launches set to be realized in early 2015.

Nektar leaves fiscal-year 2014 with $262.8M in cash, this according to a presentation at the J.P. Morgan 2015 Healthcare Conference on January 13th. With a burn rate of roughly $70M per quarter, and those hefty milestone payments from AstraZeneca fast approaching, Nektar has plenty of cash to last well into 2016.

Top-line Data From the Pivotal Phase III BEACON Trial Will be Revealed in March

We don't yet know whether the BEACON trial in the crowded therapeutic space of 4th, 5th and 6th line metastatic breast cancer will be a success… Read More …